Allarity Therapeutics logo

Allarity TherapeuticsNASDAQ: ALLR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 December 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$5.36 M
-99%vs. 3y high
12%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
23%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Sat, 23 Nov 2024 00:59:34 GMT
$1.21-$0.06(-4.72%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ALLR Latest News

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
globenewswire.com18 November 2024 Sentiment: POSITIVE

Boston (November 18, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today provided a corporate update highlighting three significant developments: extended treatment duration for patients in its ongoing Phase 2 stenoparib trial, a strengthened cash position supporting initiation of a follow-up FDA registrational trial, and new revenue-generating activities from Allarity's laboratory services.

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
businesswire.com12 November 2024 Sentiment: NEGATIVE

LOS ANGELES--(BUSINESS WIRE)--ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR
accesswire.com12 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-06952, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

DEADLINE TOMORROW: Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm
accesswire.com11 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 17, 2022 and July 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2024.

FINAL ALLR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Allarity Therapeutics, Inc. Investors to Join the Class Action Lawsuit!
accesswire.com11 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Allarity securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period").

ALLR Shareholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
accesswire.com10 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 10, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Allarity securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period").

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR
prnewswire.com10 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR) and certain officers.  The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-06952, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
globenewswire.com09 November 2024 Sentiment: NEGATIVE

NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline.

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm
accesswire.com09 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 17, 2022 and July 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2024.

ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
businesswire.com08 November 2024 Sentiment: NEGATIVE

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. Allarity is a clinical-stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Fi.

What type of business is Allarity Therapeutics?

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

What sector is Allarity Therapeutics in?

Allarity Therapeutics is in the Healthcare sector

What industry is Allarity Therapeutics in?

Allarity Therapeutics is in the Biotechnology industry

What country is Allarity Therapeutics from?

Allarity Therapeutics is headquartered in United States

When did Allarity Therapeutics go public?

Allarity Therapeutics initial public offering (IPO) was on 21 December 2021

What is Allarity Therapeutics website?

https://www.allarity.com

Is Allarity Therapeutics in the S&P 500?

No, Allarity Therapeutics is not included in the S&P 500 index

Is Allarity Therapeutics in the NASDAQ 100?

No, Allarity Therapeutics is not included in the NASDAQ 100 index

Is Allarity Therapeutics in the Dow Jones?

No, Allarity Therapeutics is not included in the Dow Jones index

When was Allarity Therapeutics the previous earnings report?

No data

When does Allarity Therapeutics earnings report?

Next earnings report date is not announced yet